Madagascar can build stronger health systems to fight plague and prevent the next epidemic

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 6 January 2018)

Viewpoints
Madagascar can build stronger health systems to fight plague and prevent the next epidemic
Matthew H. Bonds, Mohammed A. Ouenzar, Andres Garchitorena, Laura F. Cordier, Meg G. McCarty, Michael L. Rich, Benjamin Andriamihaja, Justin Haruna, Paul E. Farmer
| published 04 Jan 2018 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0006131
… The outbreak was officially detected a week later, preceding the infection of more than 2,200 confirmed, probable, and suspected cases as of November 2017, making it one the world’s worst plague epidemics in the past half century [2,3]. Though curable with antibiotics if detected early, more than 200 people have died.
The response of the international community and the national government brought the epidemic significantly under control after some initial delay. Rapid diagnostic tests (RDTs), antibiotics, and protective gear arrived in the capital en masse and were distributed with a host of international actors. Widespread sensitization campaigns were implemented, patients were identified and treated, and thousands of community health workers (CHWs) conducted contact tracing to prevent the spread. However, supply chains and infrastructure throughout Madagascar are weak, and there have been persistent shortages of needed equipment and materials in exposed regions that are traditionally at low risk of plague. The lack of RDTs at many health facilities meant that many cases went unrecognized or were treated empirically at advanced stages, resulting in unchecked transmissions, including to as many as 70 health workers [1]. The risk of a larger epidemic spreading throughout the country this year is now low, but with the seasonal dynamics typically peaking in December and January, vigilance remains critical…

Ten failings in global neglected tropical diseases control

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 6 January 2018)

Editorial
Ten failings in global neglected tropical diseases control
Peter J. Hotez
| published 21 Dec 2017 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0005896
Over the course of the last decade, the global community has made tremendous progress towards neglected tropical disease (NTD) control or even elimination, especially for some of the 20 conditions now recognized by the World Health Organization (WHO) [1]. However, there remain important and substantive gaps in our achievements. Some of these gaps are glaring and obvious, and the fact that they continue to be ignored by global leaders and policymakers approaches a moral failing or outrage. Listed here are 10 of what I consider to be our greatest missed opportunities, including some that I previously highlighted as priorities for the new WHO Director-General, Dr. Tedros [2]…

PLoS One [Accessed 6 January 2018]

PLoS One
http://www.plosone.org/
[Accessed 6 January 2018]

Research Article
Impact of influenza vaccine on childhood otitis media in Taiwan: A population-based study
Pei-Wen Wu, Chien-Chia Huang, Wei-Chieh Chao, Chi-Chin Sun, Cheng-Hsun Chiu, Ta-Jen Lee
| published 05 Jan 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0190507

Research Article
High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns
Zizipho Z. A. Mbulawa, Cari van Schalkwyk, Nai-Chung Hu, Tracy L. Meiring, Shaun Barnabas, Smritee Dabee, Heather Jaspan, Jean-Mari Kriek, Shameem Z. Jaumdally, Etienne Muller, Linda-Gail Bekker, David A. Lewis, Janan Dietrich, Glenda Gray, Jo-Ann S. Passmore, Anna-Lise Williamson
| published 02 Jan 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0190166

Research Article
Maternal influenza vaccine strategies in Kenya: Which approach would have the greatest impact on disease burden in pregnant women and young infants?
Meredith L. McMorrow, Gideon O. Emukule, David Obor, Bryan Nyawanda, Nancy A. Otieno, Caroline Makokha, Joshua A. Mott, Joseph S. Bresee, Carrie Reed
| published 28 Dec 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0189623

 

Self-reported influenza vaccination rates and attitudes towards vaccination among health care workers: results of a survey in a German university hospital

Public Health
January 2018  Volume 154
http://www.publichealthjrnl.com/current

Original Research
Self-reported influenza vaccination rates and attitudes towards vaccination among health care workers: results of a survey in a German university hospital
M.H. Hagemeister, N.K. Stock, T. Ludwig, P. Heuschmann, U. Vogel
p102–109
Published online: December 5, 2017

Vaccination of dogs in an African city interrupts rabies transmission and reduces human exposure

Science Translational Medicine
http://stm.sciencemag.org/
03 January 2018  Vol 10, Issue 422
[New issue; No digest content identified]

20 December 2017  Vol 9, Issue 421
Report
Vaccination of dogs in an African city interrupts rabies transmission and reduces human exposure
By Jakob Zinsstag, Monique Lechenne, Mirjam Laager, Rolande Mindekem, Service Naïssengar, Assandi Oussiguéré, Kebkiba Bidjeh, Germain Rives, Julie Tessier, Seraphin Madjaninan, Mahamat Ouagal, Daugla D. Moto, Idriss O. Alfaroukh, Yvonne Muthiani, Abdallah Traoré, Jan Hattendorf, Anthony Lepelletier, Lauriane Kergoat, Hervé Bourhy, Laurent Dacheux, Tanja Stadler, Nakul Chitnis
Science Translational Medicine20 Dec 2017 Restricted Access
A citywide dog vaccination effort in Chad reduced the local spread of rabies from dogs to humans.
Abstract
Despite the existence of effective rabies vaccines for dogs, dog-transmitted human rabies persists and has reemerged in Africa. Two consecutive dog vaccination campaigns took place in Chad in 2012 and 2013 (coverage of 71% in both years) in the capital city of N’Djaména, as previously published. We developed a deterministic model of dog-human rabies transmission fitted to weekly incidence data of rabid dogs and exposed human cases in N’Djaména. Our analysis showed that the effective reproductive number, that is, the number of new dogs infected by a rabid dog, fell to below one through November 2014. The modeled incidence of human rabies exposure fell to less than one person per million people per year. A phylodynamic estimation of the effective reproductive number from 29 canine rabies virus genetic sequences of the viral N-protein confirmed the results of the deterministic transmission model, implying that rabies transmission between dogs was interrupted for 9 months. However, new dog rabies cases appeared earlier than the transmission and phylodynamic models predicted. This may have been due to the continuous movement of rabies-exposed dogs into N’Djaména from outside the city. Our results show that canine rabies transmission to humans can be interrupted in an African city with currently available dog rabies vaccines, provided that the vaccination area includes larger adjacent regions, and local communities are informed and engaged.

Measles and Rubella Global Strategic Plan 2012–2020 midterm review

Vaccine
Volume 36, Supplement 1 Pages A1–A42 (11 January 2018)
http://www.sciencedirect.com/journal/vaccine/vol/36/suppl/S1
Midterm Review of the Global Measles and Rubella Strategic Plan, 2012-2020

Review article
Measles and Rubella Global Strategic Plan 2012–2020 midterm review
Open access – Pages A1-A34
W.A. Orenstein, A. Hinman, B. Nkowane, J.M. Olive, A. Reingold
Abstract
Measles, a vaccine-preventable illness, is one of the most infectious diseases known to man. In 2015, an estimated 134,200 measles deaths occurred globally. Rubella, also vaccine-preventable, is a concern because infection during pregnancy can result in congenital defects in the baby. More than 100,000 babies with congenital rubella syndrome were estimated to have been born globally in 2010. Eradication of both measles and rubella is considered to be feasible, beneficial, and more cost-effective than high-level control. All six World Health Organization (WHO) regions have measles elimination goals by 2020 and two have rubella elimination goals by that year. However, the World Health Assembly has not endorsed a global eradication goal for either disease. In 2012, the Measles and Rubella Initiative published a Global Measles and Rubella Strategic Plan, 2012–2020, referred to hereafter as the Plan, which aimed to achieve measles and rubella elimination in at least five WHO regions by end-2020 through the implementation of five core strategies, with progress evaluated against 2015 milestones. When, by end-2015, none of these milestones had been met, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended a mid-term review of the Plan to evaluate progress toward goals, assess the quality of strategy implementation, and formulate lessons learned. A five-member team reviewed documents and conducted interviews with stakeholders as the basis for the review’s conclusions and recommendations. This team concluded that, although significant progress in measles elimination had been made, progress had slowed. It recommended that countries continue to work toward elimination goals with a focus on strengthening ongoing immunization systems. In addition, it concluded that the strategies articulated in the Plan were sound, however full implementation had been impeded by inadequate country ownership and global political will, reflected in inadequate resources. Detailed recommendations for each of the Plan’s five strategies as well as the areas of polio transition, governance and resource mobilization are outlined.

Measles and Rubella Global Strategic Plan 2012–2020 midterm review report: Background and summary

Vaccine
Volume 36, Supplement 1 Pages A1–A42 (11 January 2018)
http://www.sciencedirect.com/journal/vaccine/vol/36/suppl/S1
Midterm Review of the Global Measles and Rubella Strategic Plan, 2012-2020

Measles and Rubella Global Strategic Plan 2012–2020 midterm review report: Background and summary
Open access – Pages A35-A42
Walter A. Orenstein, Lisa Cairns, Alan Hinman, Benjamin Nkowane, … Arthur L. Reingold

 

Vaccine Volume 36, Issue 1 Pages 1-190 (2 January 2018)

Vaccine
Volume 36, Issue 1 Pages 1-190 (2 January 2018)
http://www.sciencedirect.com/journal/vaccine/vol/36/issue/1

Commentary
Measles and rubella eradication
Pages 1-3  Alan R. Hinman

Review
Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015
Review article
Pages 6-14
Lana Childs, Sigrun Roesel, Rania A. Tohme

Parental perceptions, attitudes and acceptance of childhood immunization in Saudi Arabia: A cross sectional study
Original research article
Pages 23-28
Thamir M. Alshammari, Gehad M. Subaiea, Talib Hussain, Afrasim Moin, Kazeem B. Yusuff

Knowledge, attitudes, and practices of private sector immunization service providers in Gujarat, India
Original research article
Pages 36-42
José E. Hagan, Narayan Gaonkar, Vikas Doshi, Anas Patni, … Margaret Watkins

Immunization effects of a communication intervention to promote preteen HPV vaccination in primary care practices
Original research article
Pages 122-127
Joan R. Cates, Jamie L. Crandell, Sandra J. Diehl, Tamera Coyne-Beasley

Impact of measles supplementary immunization activities on reaching children missed by routine programs
Open access – Original research article
Pages 170-178
Allison Portnoy, Mark Jit, Stéphane Helleringer, Stéphane Verguet
 

Influenza Vaccination Rates Among Parents and Health Care Personnel in a German Neonatology Department

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 6 January 2018)

Open Access  Article
Influenza Vaccination Rates Among Parents and Health Care Personnel in a German Neonatology Department
by Horst Buxmann, Anne Daun, Sabine Wicker and Rolf Lambert Schlößer
Vaccines 2018, 6(1), 3; doi:10.3390/vaccines6010003 (registering DOI) – 5 January 2018
Abstract
The influenza vaccination is recommended for all German pregnant women and health care personnel (HCP). We are the first to publish vaccination rates of mothers of hospitalized newborns and HCP in neonatal units. Between September 2016 and March 2017, data were collected in our level-III neonatology department in this descriptive multidisciplinary study, using an anonymous questionnaire. As a result, 513 persons were asked to participate, including 330 parents and 183 HCP. We received an 80.3% (412/513) response rate, 87.3% (288/330), and 67.8% (124/183) from parents and HCP, respectively. Ten percent (16/160) of mothers and 4.7% (6/127) of fathers had been vaccinated in 2016–2017 and 54.4% (87/160) mothers and 52.2% (66/127) fathers ever in their lifetime. In 2016–2017, 51.2% (21/41) of physicians had been vaccinated, 25.5% (14/55) of nurses, and 50.0% (14/28) of other staff members. When comparing those who had more than five influenza vaccinations in their life time, physicians were at 43.9% (18/41) versus nurses at 10.9% (6/55) (p < 0.01), and other HCP at 7.4% (2/27) (p < 0.01). The influenza vaccine uptake rate of 10% in mothers of hospitalized neonates is disappointingly low, resulting in 90% of hospitalized neonates being potentially vulnerable to influenza infection at a time where the risk for influenza-related complication can be severe

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

 
American Journal of Obstetrics and Gynecology
January 2018 Volume 218, Issue 1, Supplement, Pages S516–S5
http://www.ajog.org/issue/S0002-9378(17)X0012-4
867: Cost-Effectiveness of the Tdap Vaccine During Pregnancy
BM Ameel, RH Beigi, AB Caughey –
Abstract
Objective
Despite recommendations from the CDC’s Advisory Committee on Immunization Practice and ACOG, tetanus, diphtheria, and acellular pertussis (Tdap) vaccination rates during pregnancy remain very low at about 10%. Vaccinating pregnant women confers passive immunity to infants against pertussis, who experience significantly higher mortality from whooping cough. We sought to highlight the importance of this recommendation by assessing the cost-effectiveness of the Tdap vaccine in pregnant women for preventing pertussis infection in infants.
Study Design
We developed a decision-analytic model in TreeAge to assess the cost-effectiveness of vaccinating healthy pregnant women with the Tdap vaccine. Neonatal outcomes assessed included neonatal death and encephalopathy. All probabilities and costs were derived from the literature. Utilities were applied to discounted life expectancy at a discount rate of 3% to generate quality adjusted life years (QALYs). Sensitivity analyses were performed to assess the robustness of our model to changes in baseline.
Results
We found that vaccinating pregnant women according to current guidelines is the cost-effective strategy. For every 100,000 women vaccinated, 3 neonatal deaths, and 0.6 encephalopathy cases were avoided, and 99 QALYs were gained. With a baseline assumption of the cost of vaccine of $37.55, vaccination was cost effective at $19,659.20 per QALY. The results of the model remain cost-effective in sensitivity analyses that vary baseline prevalence of pertussis in infants to 1%, vaccine effectiveness down to 20%, and cost of the vaccine up to $100.00.
Conclusion
OB providers should ensure that pregnant women receive the Tdap vaccine during pregnancy, especially given recent data that show postpartum maternal vaccination and cocooning strategies are not effective. Public health strategies to encourage greater uptake of the Tdap vaccination should be employed.
 
 
Health Economics
[01 Dec 2017, 26 Suppl 3:66-75]
Behavioural consequences of vaccination recommendations: An experimental analysis.
R Böhm, NW Meier, L Korn, C Betsch
Abstract
Annual vaccination is the most effective way to prevent seasonal influenza. However, globally, the recommendations vary from country to country, ranging from universal recommendations, risk-group-specific recommendations, to no recommendation at all. Due to high diversity both in recommendation practice and country-specific preconditions, it is difficult to determine the effect of different recommendations on vaccine uptake. This incentivised laboratory experiment (N = 288) tests the behavioural consequences of different recommendations in a repeated interactive vaccination game. The participants are part of heterogeneous groups, comprised of low- and high-risk type of players. They receive either a universal, risk-group-specific or no recommendation prior to their vaccination decisions. Results show that individuals are sensitive to the recommendations. In detail, a risk-group-specific recommendation increases vaccine uptake of high-risk types. However, at the same time, it decreases vaccine uptake of low-risk types. The results imply that when the proportion of low-risk types in a population is considerably larger than the high-risk group, a risk-group-specific (vs. universal) recommendation comes at the cost of decreased social benefit of vaccination due to the overall lower vaccine uptake. Policy decision-making should therefore complement epidemiological considerations with potential positive and negative behavioural consequences of vaccination recommendations.
 
 
Pediatrics International
Accepted manuscript online: 30 December 2017
A questionnaire survey for parents in Nara prefecture, Japan about mumps vaccination
T Kitano, H Nishikawa, M Onaka, M Ishihara…
Although the mumps vaccine has not been included in the national immunization program (NIP) in Japan, it has been shown that a two-dose routine vaccine program would be highly cost-effective. In this study, we performed a questionnaire-based study to investigate how many Japanese parents want the mumps vaccine to be included in the NIP with proper information.
 

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 

CNN
http://edition.cnn.com/
Accessed 6 January 2018
How countries around the world try to encourage vaccination
2 January 2018
A new policy in France requires all children born January 1 or later to receive 11 mandatory vaccines. Vaccines against diphtheria, tetanus and poliomyelitis have always been mandatory in France, while eight — including whooping cough, hepatitis B, measles, mumps and rubella — had been recommended. As of New Year’s Day, the additional eight are mandatory…
 
 
The Guardian
http://www.guardiannews.com/
Accessed 6 January 2018
Ebola survivors sue government of Sierra Leone over missing Ebola millions
Stewardship of $15m in foreign support for deadly outbreak under scrutiny as officials are accused of failing to honour promises
5 January 2018
Two Ebola survivors are to sue the government of Sierra Leone in the first international court case intended to throw light on what happened to some of the millions of dollars siphoned off from funding to help fight the disease.
The case, filed with the regional west African court in Nigeria, alleges that a lack of government accountability allowed the disappearance of almost a third of the money that came into the country during the early months of the Ebola outbreak in 2014. It claims that this led to violations of survivors’ rights to health and life…

 
New York Times
http://www.nytimes.com/
Accessed 6 January 2018
Suspected Diphtheria Cases in Yemen Near 500-WHO
At least 471 people in Yemen are believed to have been infected with diphtheria, killing one in 10 of them since the outbreak began in mid-August, the World Health Organization (WHO) said on Thursday.
January 04, 2018 – By REUTERS –

In World’s Worst Cholera Outbreak, Vaccine Talks Hang in the Balance
A cholera epidemic in Yemen, one of the worst ever recorded, is likely to surge again around March, giving global health experts a few months to get vaccines in to the war-torn country to try to limit the next wave of cases.
December 29, 2017 – By REUTERS

Vaccines and Global Health: The Week in Review 16 December 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_16 Dec 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Editor’s Note: We will resume publication on 6 January 2018 following the end-of-year holiday period.

Tokyo Declaration on Universal Health Coverage: All Together to Accelerate Progress towards UHC

Milestones :: Perspectives
 
Editor’s Note:
Universal Health Coverage [UHC] has become the nexus for much global health strategy and  governance focus in the larger context of Sustainable Development Goals/Agenda 2030 context. We present the full text of a joint statement underscoring UHC’s integrating role and a supporting press release below.

Tokyo Declaration on Universal Health Coverage: All Together to Accelerate Progress towards UHC
Statement December 14, 2017 – World Bank, WHO, UNICEF, JICA, UHC2030
Universal Health Coverage Forum 2017
[full text; editor’s text bolding]
 
We, the Co-Organizers of the Universal Health Coverage (UHC) Forum, reaffirm our commitment to accelerating progress towards UHC, and to achieving health for all people, whoever they are, wherever they live, by 2030.

We recognise the integrated and indivisible nature of the Sustainable Development Goals (SDGs), which balance the economic, social and environmental dimensions of sustainable development.

We reiterate the importance of target 3.8 of the SDGs, which seeks to provide all people with access to high-quality, integrated, “people-centred” health services. This must include promotive, preventive, curative, rehabilitative and palliative health services, as well as safe, effective, quality and affordable essential medicines and vaccines. We want to ensure that people do not suffer financial hardship when accessing services. We emphasize the importance of protecting all people from health risks such as outbreaks, and responding rapidly to outbreaks and crises.

We acknowledge that health is a human right and that UHC is essential to health for all and to human security. We adhere to the principle of Leaving No One Behind, which requires special effort to design and deliver health services informed by the voices and needs of people. This prioritizes the most vulnerable members of the world’s population — children and women — those affected by emergencies, refugees and migrants, and marginalized, stigmatized and minority populations, so often living in extremely difficult circumstances.

We affirm that UHC is both technically and financially feasible. UHC produces high returns across the life course and drives employment and inclusive economic growth. UHC is one of the cornerstones of the Sustainable Development Agenda and contributes to progress towards all SDGs. Without UHC, billions of people are at risk of losing the opportunity to live full and productive lives, and hundreds of millions risk impoverishment in their pursuit of health care. Millions of people live in countries and states considered to be fragile. Attaining UHC in these settings requires strong intersectoral collaboration.

We reaffirm and build on the G7 Ise-Shima Vision for Global Health, the TICAD VI Nairobi Declaration, which acknowledges the “UHC in Africa: A Framework for Action.” We also build on the G20 Berlin Declaration, which acknowledges the UHC2030 “Healthy systems for universal health coverage – a joint vision for healthy lives,” as well as other regional and international declarations. All of these stress the need to build and strengthen resilient and sustainable health systems and prepare for public health emergencies in an integrated way. In this context, we note the progress that has been made to reinforce preparedness and responses to public health emergencies, including formalization of coordination mechanisms among the World Health Organization (WHO) and other relevant United Nations (UN) partners, and funding mechanisms for emergencies like the WHO’s Contingency Fund for Emergencies (CFE) and the World Bank’s Pandemic Emergency Financing Facility (PEF).

We welcome the release of the 2017 UHC Global Monitoring Report. According to this report, much remains to be done to achieve UHC:  
   :: At least half of the world’s population still does not have access to quality essential services to protect and promote health. 
   :: 800 million people are spending at least 10 percent of their household budget on out-of-pocket health care expenses, and nearly 100 million people are being pushed into extreme poverty each year due to health care costs.

Concerned that progress towards UHC is too slow, despite the efforts made in each country, we call for greater commitment to accelerate progress towards UHC.

Strengthening global momentum towards UHC
:: By 2023, the midpoint towards 2030, the world needs to extend essential health coverage to 1 billion additional people and halve to 50 million the number of people being pushed into extreme poverty by health expenses.

:: We commit to monitoring progress towards UHC as part of the UN SDG review process by issuing global monitoring reports regularly, and reviewing key findings at the subsequent UHC Forum. We welcome the use of a uniform measurement methodology for UHC indicators in the 2017 Global Monitoring Report. We also emphasize the importance of strengthening the breadth and depth of data at the national and subnational levels, including disaggregated data, to inform evidence-based policymaking and to assess progress, as well as strengthening the capacity of local stakeholders to analyse and use data.

:: In response to the recommendations of the UN Secretary-General’s High-Level Commission on Health Employment and Economic Growth, and as articulated in the Dublin Declaration on Human Resources for Health, we call upon all relevant stakeholders to expand and transform investments in the health and social workforce for UHC, emphasizing the empowerment of women and youth employment.

:: To maintain a high level of political momentum on UHC, we welcome the 40th anniversary conference in 2018 of the Alma Ata Declaration, from the International Conference on Primary Health Care. We also welcome the decision to designate December 12 of each year as International UHC Day and support the UN high-level meeting on UHC in 2019. Furthermore, we will support stronger global leadership at high level of the UN system to promote UHC.

Accelerating country-led process towards UHC
:: We commit to jointly mobilizing political leadership around the world so that countries develop their own roadmaps towards UHC, with clearly indicated targets, indicators and specific plans. We support the increased alignment of efforts among all development partners through country-led, multi-stakeholder coordination platforms in line with the UHC2030 Global Compact principles. We also promote country-level engagement with diverse stakeholders from non-governmental and private sector partners to enhance shared ownership and accountability. We welcome the contribution of international initiatives such as the Tokyo Joint UHC Initiative, the UHC Partnership, Providing for Health Partnership, and the Global Financing Facility (GFF), which aim to strengthen country systems and platforms for UHC and preparedness in a collaborative manner.

   :: In pursuing UHC, we commit to targeted investments to prevent, detect and respond to disease outbreaks and other emergencies including surveillance systems in order to safeguard health security and international collaboration under the International Health Regulations (2005). In doing so, we will promote a focus on fragile and conflict-affected settings to ensure UHC financing in such settings. We also commit to investing in building a sound foundation for healthy societies with equitable access to social services such as water, sanitation, nutrition, housing, and education, and mainstreaming gender throughout policies and programmes.

: On financing for UHC, we support a strong dialogue between the Ministries of Health and Finance to mobilize and manage domestic resources to increase public funding and reduce out-of-pocket payments. It is also critical for countries to mobilise citizen and community platforms, strengthening their budgetary processes, tracking expenditures to achieve value and equity of health spending, and enhancing the efficiency of health expenditures.

: Effective and innovative financing tools offered by development partners, such as the GFF and World Bank’s IDA, also complement domestic resources. In this regard, we welcome IDA18’s strong policy commitment to the global health agenda, which was supported by Japan and other donors, and look forward to further mobilization of IDA funds to promote UHC. We also call for expanded financing and increased alignment to support UHC by all development partners, particularly multilateral development banks and Global Health Initiatives such as the Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund) and Gavi, the Vaccine Alliance, and foundations such as Bill and Melinda Gates Foundation. In order to further promote financing for UHC, we will explore holding a high-level dialogue with Health and Finance Ministries by 2019.

Innovation for UHC
:: We recognise that realising our ambition requires going beyond “business as usual,” and commit to developing and supporting strategies, policies and systems at the global and country level to harness and sustain the transformative potential of innovation. This commitment recognises the need for countries to articulate their local priorities for UHC and share best practices.

:: We also commit to improving access to medicines and vaccines through collaborative work and research and development, including during health emergencies building on platforms such as the Global Health Innovative Technology Fund (GHIT), the Coalition for Epidemic Preparedness and Innovations (CEPI) and the International AIDS Vaccine Initiative (IAVI). 

:: Accelerating progress towards UHC requires systematic learning from country experience through platforms such as UHC2030, increased focus on policy coherence, addressing implementation bottlenecks, and harnessing the potential of system innovations and effective and affordable technology in the health sector. We commit to stimulate learning on innovation for UHC by accelerating the generation and sharing of critical knowledge by building on and enhancing coordination of existing and future networks.

We look forward to future convenings and sharing the progress made towards UHC with the Global Community, in the context of the World Health Assembly, the High-Level Political Forum on Sustainable Development and the UN General Assembly, upcoming high-level UHC meetings such as the 2018 40th Anniversary of Alma Ata, and at the next UHC Forum. We extend our deep appreciation to the Government of Japan for its commitment to supporting the continuation of the UHC Fora in the future.

World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses

Press release

World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses
TOKYO, December 13, 2017 — At least half of the world’s population cannot obtain essential health services, according to a new report from the World Bank and the World Health Organization. And each year, large numbers of households are being pushed into poverty because they must pay for health care out of their own pockets…

The findings, released today in Tracking Universal Health Coverage: 2017 Global Monitoring Report, have been simultaneously published in Lancet Global Health….

“It is completely unacceptable that half the world still lacks coverage for the most essential health services,” said Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization. “And it is unnecessary. A solution exists: universal health coverage (UHC) allows everyone to obtain the health services they need, when and where they need them, without facing financial hardship.”

“The report makes clear that if we are serious – not just about better health outcomes, but also about ending poverty – we must urgently scale up our efforts on universal health coverage,” said World Bank Group President Dr. Jim Yong Kim. “Investments in health, and more generally investments in people, are critical to build human capital and enable sustainable and inclusive economic growth. But the system is broken: we need a fundamental shift in the way we mobilize resources for health and human capital, especially at the country level. We are working on many fronts to help countries spend more and more effectively in people, and increase their progress towards universal health coverage.”…

The report is a key point of discussion at the global Universal Health Coverage Forum 2017, currently taking place in Tokyo, Japan. Convened by the Government of Japan, a leading supporter of UHC domestically and globally, the Forum is cosponsored by the Japan International Cooperation Agency (JICA), UHC2030, the leading global movement advocating for UHC, UNICEF, the World Bank, and WHO. Japanese Prime Minister Shinzo Abe, UN Secretary-General Antonio Guterres, World Bank President Kim, WHO Director-General Tedros and UNICEF Executive Director Anthony Lake will all be in attendance, in addition to heads of state and ministers from over 30 countries. ..

The Forum is the culmination of events in over 100 countries, which began on Dec. 12—Universal Health Coverage Day—to highlight the growing global momentum on UHC. It seeks to showcase the strong high-level political commitment to UHC at global and country levels, highlight the experiences of countries that have been pathfinders on UHC progress, and add to the knowledge base on how to strengthen health systems and effectively promote UHC…

“Without health care, how can children reach their full potential? And without a healthy, productive population, how can societies realize their aspirations?” said UNICEF Executive Director Anthony Lake. “Universal health coverage can help level the playing field for children today, in turn helping them break intergenerational cycles of poverty and poor health tomorrow.”

UNICEF: New funding will allow countries to secure sustainable vaccine supplies and reach children more quickly

UNICEF: New funding will allow countries to secure sustainable vaccine supplies and reach children more quickly

Initiative to support countries’ vaccine supply through bridge financing receives financial boost from the Bill and Melinda Gates Foundation

COPENHAGEN, 13 December 2017 – UNICEF announced today that funding for its Vaccine Independence Initiative (VII), a mechanism to help countries secure a sustainable supply of life-saving vaccines, has more than doubled in the past year, increasing from $15 million to $35 million.

The increase was made possible especially by a $15 million financial guarantee from the Bill & Melinda Gates Foundation, adding to a VII capital base that also includes recent contributions from Gavi, the Vaccine Alliance, and the United States Fund for UNICEF.

Over 60 low-income countries currently benefit from Gavi support to purchase life-saving vaccines. As countries’ economies grow and transition away from Gavi support, the VII gives them access to short-term bridge “loans” so that they can purchase vaccines while waiting for the release of national budget funds. In addition, it provides countries assistance to strengthen the planning and budgeting processes to manage their essential supplies procurement moving forward.

VII is one tool to help countries minimize vaccine stock-outs and ensure more children receive vaccines on time. Since 2016, it has helped provide an estimated 91 million doses to children in 23 countries faster than would have otherwise been possible.

“Financing mechanisms such as the VII are an essential part of a vaccine supply financing toolkit to improve financial sustainability and ensure supplies are reaching children when they are most needed,” Shanelle Hall, UNICEF Deputy Executive Director for Field Results, explained. “We look forward to continuing our work supporting countries, together with the Foundation and other donors and partners. It is especially critical now, in light of many countries graduating from donor support, inequities in Middle Income Countries and the broader Sustainable Development Goals agenda.”…

Recent contributions to the VII have been key to support countries who are expanding their national budgets to purchase vaccines, such as Kenya and Chad. Additionally, the recently increased size of VII has allowed the new countries such as Uzbekistan, Cote d’Ivoire, and most recently Tajikistan to sign-up to the mechanism. More countries are in active discussions for new subscriptions. These efforts contribute to providing sustained immunization supplies to an increasing number of newborns in these countries.

New Michelson Prizes for Human Immunology and Vaccine Research launch

New Michelson Prizes for Human Immunology and Vaccine Research launch

The Michelson Medical Research Foundation and the Human Vaccines Project announce young investigator prizes to advance the development of future vaccines and therapies to defeat major global diseases
December 13, 2017, LOS ANGELES and NEW YORK – The Michelson Medical Research Foundation (MMRF) together with the Human Vaccines Project announced today the establishment of the Michelson Prizes for Human Immunology and Vaccine Research. The $20 million initiative, funded by the MMRF and administered by the Human Vaccines Project, aims to support young investigators applying innovative research concepts and disruptive technologies to significantly advance the development of future vaccines and therapies to defeat major global diseases.

A rigorous and competitive global search will be undertaken to identify the most innovative projects by young scientists across a broad spectrum of scientific fields. Two investigators under the age of 35 will each be awarded a $150,000 prize. To be considered, applicants need to show how they are going beyond conventional approaches in their field and clearly articulate how their contribution will make a lasting impact on human immunology and vaccine research.

“The Prizes give young scientists the freedom to think outside-of-the-box and explore disruptive technologies,” said Gary Michelson, MD, Founder of the Michelson Medical Research Foundation. “Our collaboration with the Human Vaccines Project in establishing the Michelson Prizes will help unravel the complexity of the human immune system to accelerate development of vaccines and therapies for some of the world’s most threatening diseases.”

While the Michelson Prizes are focused on research outcomes in the fields of human immunology and vaccinology, early career scientists across a wide array of disciplines, including clinical research, biomedicine, bioengineering, artificial intelligence/machine learning, and nanotechnology, are encouraged to apply. Proposals will be reviewed and winners selected by a distinguished committee of internationally recognized, independent scientists….

Dengue Vaccine – Dengvaxia Update

Dengue Vaccine – Dengvaxia Update
 
Editor’s Note:
We will continue to monitor and present major announcements and milestones around Dengvaxia as below. We have not identified any press releases from Sanofi Pasteur since its 30 November 2017 announcement:
Sanofi updates information on dengue vaccine
 
 
WHO advises Dengvaxia be used only in people previously infected with dengue
13 December 2017 – Following a consultation of the Global Advisory Committee on Vaccine Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but it should not be administered to people who have not previously been infected with dengue virus.

This recommendation is based on new evidence communicated by the vaccine’s manufacturer (Sanofi Pasteur), indicating an increase in incidence of hospitalization and severe illness in vaccinated children never infected with dengue.

The WHO Global Advisory Committee on Vaccine Safety considered the company’s new results from clinical trial data analyses. Those studies indicate that increased risk of severe dengue disease in people who have never been infected affects about 15% of the vaccinated individuals. The magnitude of risk is in the order of about 4 out of every 1000 seronegative patients vaccinated who developed severe dengue disease during five years of observation. The risk of developing severe dengue disease in non-vaccinated individuals has been calculated as 1.7 per 1000 over the same period of observation. By contrast, for the 85% who have had dengue disease before immunization, there is a reduction of 4 cases of severe dengue per 1000 who are vaccinated.

The possibility of risk for seronegative people was raised by WHO and published in a position paper in July 2016: “…vaccination may be ineffective or may theoretically even increase the future risk of hospitalized or severe dengue illness in those who are seronegative at the time of first vaccination regardless of age.”[i] As this risk had at that time not been seen in the age groups for which the vaccine was licensed, WHO issued a conditional recommendation, emphasizing the use of the vaccine in populations having been previously infected with dengue virus.

To minimize illness for seronegative vaccinated people, WHO recommends enhancing measures that reduce exposure to dengue infection among populations where the vaccine has already been administered. For vaccine recipients who present with clinical symptoms compatible with dengue virus infection, access to medical care should be expedited to allow for proper evaluation, identification, and management of severe forms of the disease…
 
 
Former Philippine President Defends Controversial Dengue Programme
December 14, 2017 – By REUTERS (Reporting by Karen Lema; Editing by Robert Birsel)
MANILA — Former Philippine President Benigno Aquino defended on Thursday his decision to implement a controversial immunisation programme using a new dengue vaccine in 2016, saying it was justified with millions of people at risk of being infected by the virus.
The decision was made to help prevent a disease affecting up to 2.8 million people, Aquino told senators investigating the campaign after the company Sanofi said its Dengvaxia vaccine was to be strictly limited due to evidence it could worsen the disease in people who had not previously been exposed to the virus.
“I want to stress, before, during, and after my government decided to use Dengvaxia, nobody expressed their objection to the vaccine,” Aquino said.
Aquino approved the use of 3.5 billion pesos ($69 million) worth of government savings during his last few months in office to buy the Dengvaxia vaccine to be used for one million children in parts of the Philippines hard-hit by dengue.
“These types of drugs undergo years of development to ensure its efficacy, especially its safety,” Aquino said…
The current government of President Rodrigo Duterte stopped the immunisation programme on Dec. 1 after Sanofi issued the warning. About 830,000 children, aged 9 and older, have been inoculated with Dengvaxia.
Two Philippine congressional inquiries have begun and a criminal investigation has also been launched to determine how the danger to public health came about.
Senator Richard Gordon, chairman of the senate investigation panel, said approval and procurement for the programme went through with “unbelievable haste and phenomenal speed” given how quickly the Department of Health received funding for the campaign.
But Duterte said on Wednesday the previous government acted in good faith and that he was “not prepared to pass judgment”.
 
 
Philippines defied experts’ advice in pursuing dengue immunWecontinue to montior major annoucnements and milestones asation programme
Reuters | 10 December 2017
… Documents reviewed by Reuters that have not been disclosed until now, as well as interviews with local experts, show that key recommendations made by a Philippines Department of Health (DOH) advisory body of doctors and pharmacologists were not heeded before the program was rolled out to 830,000 children.
After Garin’s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established.
After twice meeting in January, the panel approved the state’s purchase of the vaccine on Feb 1, 2016 but recommended stringent conditions, minutes of all three meetings show.
“Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,” the FEC told Garin in a letter on that day. The letter was reviewed by Reuters.
The FEC said Dengvaxia should be introduced through small-scale pilot tests and phased implementation rather than across three regions in the country at the same time, and only after a detailed “baseline” study of the prevalence and strains of dengue in the targeted area, the FEC letter and minutes of the meetings said.
The experts also recommended that Dengvaxia be bought in small batches so the price could be negotiated down. An economic evaluation report commissioned by Garin’s own department had found the proposed cost of 1,000 pesos ($21.29) per dose was “not cost-effective” from a public payer perspective, the minutes from the meetings reveal.
For reasons that Reuters was unable to determine, these recommendations were ignored.

“VERY ANGRY”
The DOH purchased 3 million doses of Dengvaxia in one lot, enough for the required three vaccinations for each child in the proposed immunization program and paid 1,000 pesos per dose, a copy of the purchase order reviewed by Reuters shows.
It did conduct a “limited baseline study” in late February and March 2016, but the survey looked at “common illnesses” rather than the prevalence of dengue, according to guidelines issued by Garin’s office at the time and reviewed by Reuters.
Garin, who was part of the government of former president Benigno Aquino and replaced when President Rodrigo Duterte took power in June, 2016, did not respond to requests for comment on why she ignored the local experts’ recommendations.
A physician, Garin has defended her conduct and a program that she said was “implemented in accordance with WHO guidance and recommendations”.
“I understand the concern,” she told Philippine TV station ABS-CBN on Friday. “Even us, we’re also very angry when we learned about Sanofi’s announcement about severe dengue. I‘m also a mother. My child was also vaccinated. I was also vaccinated.”
DOH spokesman Lyndon Lee Suy also did not respond to text messages or questions emailed to him.
Sanofi Philippines declined comment on the Philippines government decision. However, Dr. Su-Peing Ng, Global Medical Head of Sanofi Pasteur, told Reuters: “We communicated all known benefits and risks of the vaccine to the Philippines government.”…

Emergencies

Emergencies

 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 13 December 2017 [GPEI]
:: In Pakistan, the polio eradication programme and the routine immunization programme are working hand in hand to increase vaccination coverage in urban areas.
:: Pakistan and Afghanistan are implementing sub-national rounds during the second half of December; the rounds are synchronized to ensure that all the high risk mobile populations are efficiently reached with polio vaccine.
:: Summary of newly-reported viruses this week:
Afghanistan:  Two new WPV1 positive environmental samples reported, both collected from Nangarhar province.
Pakistan: One new case of wild poliovirus type 1 (WPV1) reported in Sindh province, Pakistan. This follows the advance notification of the case last week. Two new WPV1 positive environmental samples reported, one from Sindh province, and one from Balochistan province. Syria: Four new circulating vaccine derived poliovirus type 2 (cVDPV2) cases reported, all from Deir Ez-Zor governorate.

::::::
 
Editor’s Note:
It continues to be unclear why the weekly GPEI report on new cases at country level [above] does not capture cases in Syria [below].
 
Syria cVDPV2 outbreak situation report 26, 12 December 2017
Situation update 12 December 2017
:: Four new cases of circulating vaccine-derived poliovirus (cVDPV2) were reported this week. Three cases were reported from Mayadeen district, one case from Boukamal district, Deir Ez-Zor governorate. The most recent case (by date of onset) is 21 September 2017 from Boukamal district.
:: The total number of confirmed cVDPV2 cases is 74.
:: Global Polio Eradication Initiative (GPEI) partners continue to support the Syrian Ministry of Health with planning for the second phase of the outbreak response.
:: A new environmental surveillance laboratory has been successfully established in Damascus this week. WHO has led the training of surveillance officers and staff from the Ministry of Health and Ministry of Water Resources.

::::::
::::::

WHO Grade 3 Emergencies  [to 16 December 2017]
The Syrian Arab Republic
:: Saving the lives of Syrian mothers and children
13 December 2017, Damascus, Syrian Arab Republic — Through a donation from the Government of Spain, WHO is providing medicines to support health services in 7 governorates in the Syrian Arab Republic. WHO has provided anti-D immunoglobulin injections and other medicines, including anesthetics, to health facilities in 7 governorates in Syria through a generous donation from the Government of Spain. The grant provided sufficient medicines for more than 4500 treatments
:: Syria cVDPV2 outbreak situation report 26, 12 December 2017
[See Polio above for detail]

::::::
 
WHO Grade 2 Emergencies  [to 16 December 2017]
Myanmar 
:: Bangladesh moves to protect Rohingya children from diphtheria 12 December 2017
[See joint announcement below]

::::::

Bangladesh moves to protect Rohingya children from diphtheria
COX’S BAZAR, Bangladesh, 12 December 2017 – The Government of Bangladesh, with the support of UNICEF, the World Health Organization and GAVI, the Vaccine Alliance, today launched  a vaccination campaign against diphtheria and other preventable diseases for all Rohingya children aged 6 weeks to 6 years living in 12 camps and temporary settlements near the Myanmar border.
Accelerated immunization will cover nearly 255 000 children in Ukhiya and Teknaf sub-districts in Cox’s Bazar, while the Government and health partners continue to increase support for diphtheria treatment and prevention….

::::::

South Sudan implements the second round of Oral Cholera Vaccination to enhance outbreak response efforts in high risk locations
Juba, 14 December 2017:  Cholera in South Sudan remains an important public health problem which has affected 21 571 people and resulted in 462 deaths since the onset of the outbreak on 18 June 2016. This has been the longest and largest outbreak in magnitude and geographical extent, its impact exacerbated by the protracted crisis, insecurity, displacements and declining access to safe drinking water and sanitation. Access to improved sanitation facilities across South Sudan remains at less than 10% while access to safe drinking water from improved water sources is estimated at 60%.
As part of the ongoing cholera response, the Ministry of Health of South Sudan with support from WHO and partners has deployed cholera vaccines to complement traditional cholera response strategies in several high-risk populations and locations. From the 2,178,177 doses secured by WHO in 2017, a total of 1,133,579 doses have already been deployed with 879,239 doses used during the first round and 254,340 doses utilized in second round campaigns in 16 cholera-affected and high-risk populations countrywide.
“When used alongside other interventions for improving access to safe water and sanitation, oral cholera vaccines are very effective for cholera prevention and control, giving protection to those at risk, especially when the recommended two doses are administered,” emphasized Dr Pinyi, Director General for Preventive Services at the Ministry of Health of South Sudan.
The most recent consignment of 737,819 doses, requested by WHO from the Global Task Force on Cholera Control (GTFCC) stockpile was in Juba by 11 December, 2017. The vaccines have been deployed to areas and counties with pending second round vaccination campaigns and these include Kapoeta South, Kapoeta East, Tonj East, Aburoc and Malakal Town…

::::::
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: 14 Dec 2017  Health Cluster Weekly Situation Report: Whole of Syria, Week 50 (8 – 15 December 2017)

Yemen 
:: 11 Dec 2017  Statement by the Humanitarian Coordinator for Yemen, Jamie McGoldrick, Calling on Parties to Facilitate Unimpeded Aid Delivery [EN/AR]
:: Yemen: Escalation of armed clashes and airstrikes in Sana’a City – Flash Update 2 | 7 December 2017

Iraq   
:: Iraq: Humanitarian Bulletin, November 2017 | Issued on 8 December
 
::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
ROHINGYA CRISIS
:: ISCG Situation Update: Rohingya Refugee Crisis, Cox’s Bazar – 14 December 2017

Ethiopia   
:: 12 Dec 2017  Ethiopia Humanitarian Bulletin Issue 42 | 27 Nov – 10 Dec 2017
HIGHLIGHTS
…Ethiopia launched Comprehensive Refugee Response Framework in line with pledges made at Leaders’ Summit on Refugees in September 2016.
…30,000 refugees to benefit from employment opportunities under the “Ethiopian Jobs Compact”.
…Government to phase out encampment policy over 10 years and advance out-of-camp and local integration options.

Nigeria    
:: Fact Sheet NE Nigeria: Bama, Bama LGA (as of 12 December 2017)
:: UN allocates $13.4 million to support 1 million people with life-saving aid in North-East Nigeria
(Abuja, 11 December 2017): The United Nations, through the Nigeria Humanitarian Fund, has allocated $13.4 million to help thousands of children, women and men in need of urgent humanitarian assistance in crisis-hit north-east Nigeria.
The humanitarian emergency in the northeastern Nigeria is one of the most severe in the world today, with 8.5 million people in need of life-saving aid in 2017 in the worst-affected states of Borno, Adamawa and Yobe.
The Nigeria Humanitarian Fund (NHF) allocation will help address this devastating situation by financing 24 projects in the sectors of protection, nutrition, water and sanitation, health, education, shelter and non-food items, rapid response and early recovery, targeting a total of 950,000 people…
 

WHO & Regional Offices [to 16 December 2017]

WHO & Regional Offices [to 16 December 2017]

Up to 650 000 people die of respiratory diseases linked to seasonal flu each year
14 December 2017 – Up to 650 000 deaths annually are associated with respiratory diseases from seasonal influenza, according to new estimates by the United States Centers for Disease Control and Prevention (US-CDC), WHO and global health partners.

Half the world lacks access to essential health services
13 December 2017 – At least half of the world’s population cannot obtain essential health services, according to a new report from the World Bank and WHO. And each year, large numbers of households are being pushed into poverty because they must pay for health care out of their own pockets. Currently, 800 million people spend at least 10% of their household budgets on health expenses for themselves, a sick child or other family member.
[See Milestones/Perspectives above for more detail]

Highlights
New perspectives on global health spending for universal health coverage
December 2017 – WHO global health financing report summarizes the latest internationally comparable data on health spending in all WHO Member States between 2000 and 2015. For the first time the report uses the new international classification for health expenditures in the revised System of Health Accounts.

::::::

Fact Sheets
::  Avian and other zoonotic influenza   Updated December 2017
::  Influenza (Seasonal)  Updated November 2016
::  Universal health coverage (UHC)  December 2017

::::::
 
Weekly Epidemiological Record, 15 December 2017, vol. 92, 50 (pp. 761–780)
:: Review of global influenza activity, October 2016– October 2017
:: Monthly report on dracunculiasis cases, January-October 2017

::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: The Stop Transmission of Polio (STOP) program contributes to sustain Polio eradication in South Sudan  15 December 2017
:: South Sudan implements the second round of Oral Cholera Vaccination to enhance outbreak response efforts in high risk locations  15 December 2017
:: Amid protracted and widespread violence, WHO partners with National NGOs to improve immunization coverage and save the lives of women and children in South Sudan
Juba, 15 December 2017:  The World Health Organization (WHO) is expanding on its partners’ engagement mechanisms to address critical barriers in reaching vulnerable persons including women and children with life-saving interventions in besieged and hard-to-reach areas, where access and restrictions on movement severely hinder the ability of populations to get health services.
Since 2015, an estimated 456 000 people in south-eastern Upper Nile area have not been reached with life-saving health interventions leaving critical gaps and the derailment of vaccine preventable and communicable disease control achievements. Besides, surveillance indicators have remained very sub-optimal for vaccine preventable diseases.
To improve access and reduce family and community resistance to vaccination, WHO signed an agreement with Universal Network for Knowledge and Empowerment Agency (UNKEA), a national non-governmental organization operating in South Sudan to increase access to Expanded Programme on Immunization (EPI) services to achieve the overall goal of immunizing every child against vaccine preventable diseases in four counties of the south-eastern Upper Nile.
The four counties host over 342 482 persons at risk of meningitis, 86 763 exposed to deadly effects of measles and over 91 300 children not immunized with vaccine in the past two years, says Mr Kofi Boateng, the WHO EPI Officer…
:: Saving lives through streamlined emergency care  15 December 2017
:: WHO spearheads provision of mental health services in primary healthcare facilities  15 December 2017
:: South Sudan is getting closer to becoming free from Guinea-worm disease  14 December 2017
:: The Ministry of Health and World Health organization Conclude a 3-day advanced Infection Prevention Control (IPC)Follow Up training Workshop for County and Hospital IPC Focal Persons
14 December 2017
:: South Sudan adopts a new strategy to reduce deaths from cholera by 90 percent by 2030
14 December 2017
:: WHO reaffirms its support for initiatives and networks for harmonization and convergence of regulatory practices for Medicines in Africa  12 December 2017
:: WHO donates cholera kits to support the cholera outbreak response in the country  12 December 2017

WHO Region of the Americas PAHO
:: Regional movement for universal health launched (12/13/2017)
:: PAHO Director calls for building alliances to leave no one behind on the road to universal health (12/11/2017)

WHO South-East Asia Region SEARO
:: Bangladesh moves to protect Rohingya children from diphtheria
 
WHO European Region EURO
:: Greek health reform: opening of new primary health care units 14-12-2017
:: Financial hardship linked to inadequate health coverage policies 12-12-2017
:: Systems thinking helps England plan future health and care workforce 12-12-2017
:: Belarus and WHO Europe sign new collaborative agreement 11-12-2017

WHO Eastern Mediterranean Region EMRO
:: Universal Health Coverage Day: ensuring the right to health, leaving no one behind
13 December 2017
 
WHO Western Pacific Region
:: More action needed to achieve universal health coverage in Asia and the Pacific by global deadline  13 December 2017

MMWR News Synopsis for December 14, 2017

CDC/ACIP [to 16 December 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
 
MMWR News Synopsis for December 14, 2017
Health and Development at Age 19–24 Months of 19 Children Who Were Born with Microcephaly and Laboratory Evidence of Congenital Zika Virus Infection During the 2015 Zika Virus Outbreak — Brazil, 2017
Children with congenital Zika infection and microcephaly are now getting older and falling far behind their age-appropriate milestones, showing the need for long-term followup and support. These children will continue to require specialized care from many types of healthcare providers and their caregivers as they age. A new Centers for Disease Control and Prevention (CDC) investigation shows that children born with microcephaly (small head size for age) and evidence of congenital Zika virus infection face complex health and developmental challenges at ages 19-24 months, including an inability to sit independently, difficulties with sleeping and feeding, seizures, and hearing and vision problems. A majority of the 19 children in this investigation face challenges in multiple areas.

Large Outbreak of Neisseria meningitidis Serogroup C — Nigeria, December 2016–June 2017
Although the most recent meningococcal serogroup C outbreak in Nigeria is now fully controlled, improved surveillance and outbreak preparedness at all levels of the public health system are needed. Additionally, urgently expanding the availability of vaccines effective against multiple strains of the bacteria might help reduce the risk of outbreaks in Nigeria and other high-risk countries. From December 2016-June 2017, Nigeria experienced the largest global outbreak of meningitis caused by a new strain of the bacteria N. meningitidis serogroup C (NmC); 14,542 suspected cases and 1,166 deaths were reported. Nigeria, a country in the sub-Saharan “meningitis belt,” previously experienced large outbreaks caused by meningococcal A serogroup, which declined dramatically following the introduction in 2013 of meningococcal A vaccines. National and regional evaluations of the outbreak response outlined recommendations for improving meningitis outbreak prevention, timely detection, and response. Implementing these recommendations and expanding the availability of multivalent vaccines effective against non-A serogroups will reduce future meningitis outbreaks.

Introduction of Inactivated Poliovirus Vaccine and Elimination of Vaccine-Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016
High population coverage with the sequential inactivated polio vaccine/oral poliovirus vaccine (IPV/OPV) schedule in Beijing resulted in the successful introduction of IPV in Beijing and the elimination of vaccine-associated paralytic poliomyelitis (VAPP). IPV Introduction using a sequential IPV/ OPV schedule in Beijing was associated with a good safety record, no occurrence of VAPP or other serious adverse events, and maintenance of >95 percent coverage with polio vaccines. Strong public health leadership, good operational planning, and secured resources and budget were critical to successful IPV introduction in Beijing, assuring public confidence in the safety of OPV, assuring the availability of 1-dose IPV access, and helping improve the current routine immunization system.

Announcements  

Announcements

European Medicines Agency  [to 16 December 2017]
http://www.ema.europa.eu/ema/
15/12/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017
Seven medicines recommended for approval, including an advanced therapy …

European Vaccine Initiative  [to 16 December 2017]
http://www.euvaccine.eu/news-events
14 December 2017
ZIKAVAX Annual Meeting 2017
The first annual meeting of the EU-funded project ZIKAVAX took place on 7 December 2017 at CEA,…
 
 
FDA [to 16 December 2017]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
December 15, 2017 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on new FDA efforts to support more efficient development of targeted therapies
New website streamlines how FDA updates information used to help health care providers choose an appropriate treatment for a patient’s infection
 
 
Fondation Merieux  [to 16 December 2017]
http://www.fondation-merieux.org/
December 12, 2017
REAOLAB presents the overview of phase 2 durig its 5th Steering Committee meeting held in Mali
The RESAOLAB project brought together the partners and networks members in Bamako for its 5th International Committee Meeting on 5 and 6 December 2017. This meeting was an opportunity to take stock of the achievements of phase 2 while reporting on the continuation of the program. A workshop dedicated to antimicrobial resistance, an increasing public health challenge, and a round table on the future of young researchers in West Africa, were also organized on this occasion.
 
 
GHIT Fund   [to 16 December 2017]
https://www.ghitfund.org/
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical ·
Press Room   2017.12.11      
GHIT Fund’s Strategic Plan for 2018 to 2022: Accelerating Product Development and Product Delivery for its global health innovations

TOKYO, JAPAN (December 11, 2017)—The Global Health Innovative Technology Fund (GHIT) today announced its Strategic Plan targeting the next five years (FY2018-FY2022). Comprised of four pillars—i: Research & Development (R&D), ii: Partnership for Delivery, iii: Excellence through Good Governance, iv: Financial Strategies—GHIT will continue to accelerate global health R&D through an international partnership between Japan and countries overseas.
Since its inception in April 2013 as the world’s first global health R&D public-private partnership fund, GHIT has advanced the development of therapeutics, vaccines and diagnostics for infectious disease in low and middle income countries, by galvanizing Japan’s science and pharmaceutical capabilities. To date, GHIT has invested a total of US$115M in 68 global partnerships, and 7 clinical trials are currently underway…

 
Global Fund [to 16 December 2017]
http://www.theglobalfund.org/en/news/?topic=&type=NEWS;&country=
News
Kenya and Global Fund Sign New Grants to Accelerate Response to Diseases
15 December 2017
The Global Fund and health partners in Kenya today signed six grant agreements to strengthen the response to HIV, tuberculosis and malaria. The grants aim to reach 1.3 million people with antiretroviral therapy by 2021, and drastically expand interventions to find more missing cases of TB, among other objectives.
 
 
Hilleman Laboratories   [to 16 December 2017]
http://www.hillemanlabs.org/
12th October 2017
Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)
New Delhi: Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable Rotavirus Vaccine (HSRV), Hilleman Laboratories, a joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, today announced the successful completion of Phase I/II clinical trial of its oral vaccine against the deadly Rotavirus disease.
The study was conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)…
 
 
Human Vaccines Project   [to 16 December 2017]
http://www.humanvaccinesproject.org/media/press-releases/
Public Release: 13-Dec-2017
New Michelson Prizes for Human Immunology and Vaccine Research launch
The Michelson Medical Research Foundation and the Human Vaccines Project announce young investigator prizes to advance the development of future vaccines and therapies to defeat major global diseases
[See Milestones/Perspectives above for more detail]

IVAC  [to 16 December 2017]
[Undated]
Statement on Dengvaxia® issued by Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) with support from International Vaccine Access Center
 
 
JEE Alliance  [to 16 December 2017]
https://www.jeealliance.org/
12.12.2017
Strong health systems are essential for resilience and preparedness – time for synergy and joining up
Article
Health security contributes to peace and security, democracy, economic and social stability as well as wellbeing. Strengthening health security is therefore an integral target of the SDGs…
 
 
MSF/Médecins Sans Frontières  [to 16 December 2017]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
MSF: At Least 6,700 Rohingya Killed During Attacks in Myanmar
December 14, 2017
NEW YORK/AMSTERDAM/PARIS—At least 9,000 members of the ethnic Rohingya minority died—most of them from violence— in Rakhine state, Myanmar, between August 25 and September 24, according to surveys conducted in refugee settlement camps in Bangladesh and released today by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF).

Press release
Yemen: Diphtheria Spreads as War and Blockade Leave Health System in Tatters
December 12, 2017
Doctors Without Borders/Médecins Sans Frontières (MSF) is responding to a suspected outbreak of diphtheria in Yemen, where the disease has reemerged as the country’s health system is weakened by ongoing war and a blockade on essential goods.
 
 
PATH  [to 16 December 2017]
http://www.path.org/news/index.php
Press release | December 12, 2017
Launch of ‘Be Me. Be Happy!’: A campaign to increase transgender women’s access to HIV services in Vietnam

UNAIDS [to 16 December 2017]
http://www.unaids.org/en
15 December 2017 –
UNAIDS PCB discusses discrimination in health-care settings

14 December 2017 –
Closing the HIV resource gap in Nigeria with more domestic funding

13 December 2017 –
Key populations platform in Ukraine established

12 December 2017
41st meeting of the UNAIDS Programme Coordinating Board opens

UNICEF  [to 16 December 2017]
https://www.unicef.org/media/
15 December 2017
World Bank and WHO: Half the world lacks access to essential health services, 100 million still pushed into extreme poverty because of health expenses
TOKYO, December 13, 2017 — At least half of the world’s population cannot obtain essential health services, according to a new report from the World Bank and the World Health Organization. And each year, large numbers of households are being pushed into poverty because they must pay for health care out of their own pockets.
[See Milestones/Perspectives above for more detail]

Three months after deadly hurricanes hit Caribbean islands, thousands of children still in need of assistance
PANAMA CITY, 13 December 2017 – Three months after two category-5 hurricanes – Irma and Maria – barreled through the Caribbean, causing widespread damage and loss of life, thousands of children remain in need of support across the region.

New funding will allow countries to secure sustainable vaccine supplies and reach children more quickly
COPENHAGEN, 13 December 2017 – UNICEF announced today that funding for its Vaccine Independence Initiative (VII), a mechanism to help countries secure a sustainable supply of life-saving vaccines, has more than doubled in the past year, increasing from $15 million to $35 million.
[See Milestones/Perspectives above for more detail]

Bangladesh moves to protect Rohingya children from diphtheria
COX’S BAZAR, Bangladesh, 12 December 2017 – The Government of Bangladesh, with the support of UNICEF, the World Health Organization and GAVI, the Vaccine Alliance, today launched  a vaccination campaign against diphtheria and other preventable diseases for all Rohingya children aged 6 weeks to 6 years living in 12 camps and temporary settlements near the Myanmar border.
[See Emergencies above for more detail]

Wellcome Trust  [to 16 December 2017]
https://wellcome.ac.uk/news
News / Published: 12 December 2017
Wellcome’s charitable spend reaches record levels
Wellcome spent over £1.1 billion on science, research, innovation and public engagement in 2016-17, more than ever before and double what we spent a decade ago.
 
Explainer / Published: 11 December 2017
Sharing Clinical Trial Data: what it means for you
Wellcome is joining ClinicalStudyDataRequest.com (CSDR), a data-sharing initiative involving academic research funders and pharmaceutical companies. Jen O’Callaghan, from our Open Research team, explains why and what it means for researchers.
As a global research foundation, we’re dedicated to ensuring that the outputs of the research we fund – including clinical trial data – can be accessed and used in ways that will advance medical science by building on previous findings and exploring new questions.
CSDR (opens in a new tab) is a website portal for listing and sharing clinical trial datasets. Initially established to provide a way in which researchers could access trial data from a consortium of 13 pharmaceutical companies, CSDR is now expanding to include data from academic-led trials….

::::::
 
 
IFPMA   [to 16 December 2017]
http://www.ifpma.org/resources/news-releases/
13 December 2017
10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for negected diseases
Geneva, 13 December 2017: IFPMA, the international association representing the research-based biopharmaceutical companies, welcomes the 10th annual G-FINDER report[i] results that show industry contributed USD 497m to global R&D efforts, accounting for 16% of total global funding. The report notes that industry funding has reached new record highs for the last three years. Since 2008, reported industry investment has increased by nearly 50%. This firmly consolidates industry’s position as the 3rd largest funder of R&D for neglected diseases after the US NIH and the Bill and Melinda Gates Foundation…
 

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

Spatial clustering of measles vaccination coverage among children in sub-Saharan Africa

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 December 2017)

Research article
Spatial clustering of measles vaccination coverage among children in sub-Saharan Africa
Authors: Tenley K. Brownwright, Zan M. Dodson and Willem G. van Panhuis
Citation: BMC Public Health 2017 17:957
Published on: 15 December 2017
Abstract
Background
During the past two decades, vaccination programs have greatly reduced global morbidity and mortality due to measles, but recently this progress has stalled. Even in countries that report high vaccination coverage rates, transmission has continued, particularly in spatially clustered subpopulations with low vaccination coverage.
Methods
We examined the spatial heterogeneity of measles vaccination coverage among children aged 12–23 months in ten Sub-Saharan African countries. We used the Anselin Local Moran’s I to estimate clustering of vaccination coverage based on data from Demographic and Health Surveys conducted between 2008 and 2013. We also examined the role of sociodemographic factors to explain clustering of low vaccination.
Results
We detected 477 spatial clusters with low vaccination coverage, many of which were located in countries with relatively high nationwide vaccination coverage rates such as Zambia and Malawi. We also found clusters in border areas with transient populations. Clustering of low vaccination coverage was related to low health education and limited access to healthcare.
Conclusions
Systematically monitoring clustered populations with low vaccination coverage can inform supplemental immunization activities and strengthen elimination programs. Metrics of spatial heterogeneity should be used routinely to determine the success of immunization programs and the risk of disease persistence.

Political drivers of epidemic response: foreign healthcare workers and the 2014 Ebola outbreak (pages 41–61)

Disasters
January 2018  Volume 42, Issue 1  Pages 1–203
http://onlinelibrary.wiley.com/doi/10.1111/disa.2017.41.issue-4/issuetoc

Papers
Political drivers of epidemic response: foreign healthcare workers and the 2014 Ebola outbreak (pages 41–61)
Daniel Nohrstedt and Erik Baekkeskov
Version of Record online: 25 APR 2017 | DOI: 10.1111/disa.12238
Abstract
This study demonstrates that countries responded quite differently to calls for healthcare workers (HCWs) during the Ebola epidemic in West Africa in 2014. Using a new dataset on the scale and timing of national pledges and the deployment of HCWs to states experiencing outbreaks of the virus disease (principally, Guinea, Liberia, and Sierra Leone), it shows that few foreign nations deployed HCWs early, some made pledges but then fulfilled them slowly, and most sent no HCWs at all. To aid understanding of such national responses, the paper reviews five theoretical perspectives that offer potentially competing or complementary explanations of foreign government medical assistance for international public health emergencies. The study systematically validates that countries varied greatly in whether and when they addressed HCW deployment needs during the Ebola crisis of 2014, and offers suggestions for a theory-driven inquiry to elucidate the logics of foreign interventions in critical infectious disease epidemics.

Publicly available software tools for decision-makers during an emergent epidemic—Systematic evaluation of utility and usability

Epidemics
Volume 21, Pages 1-88 (December 2017)
http://www.sciencedirect.com/science/journal/17554365

Review Articles
Publicly available software tools for decision-makers during an emergent epidemic—Systematic evaluation of utility and usability
Review Article
Pages 1-12
David James Heslop, Abrar Ahmad Chughtai, Chau Minh Bui, C. Raina MacIntyre
Abstract
Epidemics and emerging infectious diseases are becoming an increasing threat to global populations—challenging public health practitioners, decision makers and researchers to plan, prepare, identify and respond to outbreaks in near real-timeframes. The aim of this research is to evaluate the range of public domain and freely available software epidemic modelling tools. Twenty freely utilisable software tools underwent assessment of software usability, utility and key functionalities. Stochastic and agent based tools were found to be highly flexible, adaptable, had high utility and many features, but low usability. Deterministic tools were highly usable with average to good levels of utility.

The impact of current infection levels on the cost-benefit of vaccination

Epidemics
Volume 21, Pages 1-88 (December 2017)
http://www.sciencedirect.com/science/journal/17554365

Original Research Article
The impact of current infection levels on the cost-benefit of vaccination
Pages 56-62
Matt J. Keeling, Katherine A. Broadfoot, Samik Datta
Abstract
When considering a new vaccine programme or modifying an existing one, economic cost-benefit analysis, underpinned by predictive epidemiological modelling, is a key component. This analysis is intimately linked to the willingness to pay for additional QALYs (quality-adjusted life-years) gained; currently in England and Wales a health programme is economically viable if the cost per QALY gained is less than £ 20,000, and models are often used to assess if a vaccine programme is likely to fall below this threshold cost. Before a programme begins, infection levels are generally high and therefore vaccination may be expected to have substantial effects and therefore will often be economically viable. However, once a programme is established, and infection rates are lower, it might be expected that a re-evaluation of the programme (using current incidence information) will show it to be less cost-effective. This is the scenario we examine here with analytical tools and simple ODE models. Surprisingly we show that in most cases the benefits from maintaining an existing vaccination programme are at least equal to those of starting the programme initially, and in the majority of scenarios the differences between the two are minimal. In practical terms, this is an extremely helpful finding, allowing us to assert that the action of immunising individuals does not de-value the vaccination programme.

The Global Fund’s paradigm of oversight, monitoring, and results in Mozambique

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 16 December 2017]

Research
12 December 2017
The Global Fund’s paradigm of oversight, monitoring, and results in Mozambique
Authors: Ashley Warren, Roberto Cordon, Michaela Told, Don de Savigny, Ilona Kickbusch and Marcel Tanner
Abstract
Background
The Global Fund is one of the largest actors in global health. In 2015 the Global Fund was credited with disbursing close to 10 % of all development assistance for health. In 2011 it began a reform process in response to internal reviews following allegations of recipients’ misuse of funds. Reforms have focused on grant application processes thus far while the core structures and paradigm have remained intact. We report results of discussions with key stakeholders on the Global Fund, its paradigm of oversight, monitoring, and results in Mozambique.
Methods
We conducted 38 semi-structured in-depth interviews in Maputo, Mozambique and members of the Global Fund Board and Secretariat in Switzerland. In-country stakeholders were representatives from Global Fund country structures (eg. Principle Recipient), the Ministry of Health, health or development attachés bilateral and multilateral agencies, consultants, and the NGO coordinating body. Thematic coding revealed concerns about the combination of weak country oversight with stringent and cumbersome requirements for monitoring and evaluation linked to performance-based financing.
Results
Analysis revealed that despite the changes associated with the New Funding Model, respondents in both Maputo and Geneva firmly believe challenges remain in Global Fund’s structure and paradigm. The lack of a country office has many negative downstream effects including reliance on in-country partners and ineffective coordination. Due to weak managerial and absorptive capacity, more oversight is required than is afforded by country team visits. In-country partners provide much needed support for Global Fund recipients, but roles, responsibilities, and accountability must be clearly defined for a successful long-term partnership. Furthermore, decision-makers in Geneva recognize in-country coordination as vital to successful implementation, and partners welcome increased Global Fund engagement.
Conclusions
To date, there are no institutional requirements for formalized coordination, and the Global Fund has no consistent representation in Mozambique’s in-country coordination groups. The Global Fund should adapt grant implementation and monitoring procedures to the specific local realities that would be illuminated by more formalized coordination.

Special Feature: The Lake Chad Basin: an overlooked crisis?

Humanitarian Exchange Magazine
http://odihpn.org/magazine/the-humanitarian-consequences-of-violence-in-central-america/
Number 70   October 2017
Special Feature: The Lake Chad Basin: an overlooked crisis?
by Humanitarian Practice Network October 2017
The 70th edition of Humanitarian Exchange, co-edited with Joe Read, focuses on the humanitarian crisis in Nigeria and the Lake Chad Basin. The violence perpetrated by Boko Haram and the counter-insurgency campaign in Nigeria, Cameroon, Chad and Niger has created a humanitarian crisis affecting some 17 million people. Some 2.4 million have been displaced, the vast majority of them in north-eastern Nigeria. Many are living in desperate conditions, without access to sufficient food or clean water. The Nigerian government’s focus on defeating Boko Haram militarily, its reluctance to acknowledge the scale and gravity of the humanitarian crisis and the corresponding reticence of humanitarian leaders to challenge that position have combined to undermine the timeliness and effectiveness of the response…

[Reviewed earlier]

Support for research towards understanding the population health vulnerabilities to vector-borne diseases: increasing resilience under climate change conditions in Africa

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 16 December 2017]

Commentary
12 December 2017
Support for research towards understanding the population health vulnerabilities to vector-borne diseases: increasing resilience under climate change conditions in Africa
Diseases transmitted to humans by vectors account for 17% of all infectious diseases and remain significant public health problems. Through the years, great strides have been taken towards combatting vector-borne diseases (VBDs), most notably through large scale and coordinated control programmes, which have contributed to the decline of the global mortality attributed to VBDs. However, with environmental changes, including climate change, the impact on VBDs is anticipated to be significant, in terms of VBD-related hazards, vulnerabilities and exposure. While there is growing awareness on the vulnerability of the African continent to VBDs in the context of climate change, there is still a paucity of research being undertaken in this area, and impeding the formulation of evidence-based health policy change.
Authors: Bernadette Ramirez

Addressing vulnerability, building resilience: community-based adaptation to vector-borne diseases in the context of global change

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 16 December 2017]

Scoping Review
11 December 2017
Addressing vulnerability, building resilience: community-based adaptation to vector-borne diseases in the context of global change
The threat of a rapidly changing planet – of coupled social, environmental and climatic change – pose new conceptual and practical challenges in responding to vector-borne diseases. These include non-linear and uncertain spatial-temporal change dynamics associated with climate, animals, land, water, food, settlement, conflict, ecology and human socio-cultural, economic and political-institutional systems. To date, research efforts have been dominated by disease modeling, which has provided limited practical advice to policymakers and practitioners in developing policies and programmes on the ground.
Authors: Kevin Louis Bardosh, Sadie Ryan, Kris Ebi, Susan Welburn and Burton Singer

Five Ethical Values to Guide Health System Reform

JAMA
December 12, 2017, Vol 318, No. 22, Pages 2155-2265
http://jama.jamanetwork.com/issue.aspx

The JAMA Forum
Five Ethical Values to Guide Health System Reform
Lawrence O. Gostin, JD
The US health system is so mired in politics, with positions hardened by rigid ideologies, that we can’t even seem to talk with one another civilly about difficult tradeoffs. If the polity could agree on core ethical values to guide discourse, we would make hard health system choices based on which values we prefer and why. Herein, I offer 5 critical values for health system reform—universal access, equitable access, affordable access (cost), quality, and choice—explain the tradeoffs, and provide reasons why certain values should take priority. There will be disagreement across the political spectrum, but alternative visions should be justified by reasoned argument.

Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine

Journal of Infectious Diseases
Volume 216, Issue 11   1 December 2017
https://academic.oup.com/jid/issue

EDITORIAL COMMENTARIES
Editor’s Choice
Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine
Michael N Oxman; Ruth Harbecke; David M Koelle
The Journal of Infectious Diseases, Volume 216, Issue 11, 12 December 2017, Pages 1329–1333, https://doi.org/10.1093/infdis/jix484

Achieving sustainable solidarity development goals

The Lancet
Dec 16, 2017 Volume 390 Number 10113 p2605-2738  e51-e59
http://www.thelancet.com/journals/lancet/issue/current

Achieving sustainable solidarity development goals
The Lancet
The meaning of social security varies nationally. In the USA, it might bring to mind the eponymous agency that administers social insurance providing benefits for retired individuals and those living with disability. In 1934, in the wake of the Great Depression when as many as 25% of Americans were unemployed, President Franklin D Roosevelt announced his plans to create a social security programme for the nation to “encourage a greater security for each individual who composes it”. He proclaimed: “This seeking for a greater measure of welfare and happiness does not indicate a change in values. It is rather a return to values lost in the course of our economic development and expansion…”

Thus, even early in the last century and beyond the European borders where the tradition of social welfare germinated, the role of government was acknowledged amid growing tensions between national economic development and the security of individuals—a discord that persists around the world with great heterogeneity because of the patchwork of policies and programmes in place to maintain standards of social protection.

The International Labour Organization (ILO), the UN agency that oversees labour standards and liaises with workers, unions, and governments, has endeavoured to formalise a framework to monitor the state of social protection systems around the world. In late November, the ILO released its most recent publication—World Social Protection Report 2017–19: Universal social protection to achieve the Sustainable Development Goals. It is a massive undertaking, using a “life-cycle” approach to quantify social protection, from benefits extended to children and families during maternity, unemployment, disability, to the health and the financing of these security schemes.

The work of the ILO is predicated on the foundation that social security is a right and these efforts are developed in accordance with the UN’s Sustainable Development Goals (SDGs). Specifically, the report focuses on SDG 1·3, the implementation of nationally appropriate social protection systems, including floors (or defined essential levels of security), as part of the main goal to end poverty in all its forms everywhere. The 2030 Agenda for Sustainable Development incorporates related social protection goals prioritising gender equality (SDG 5·4), decent work and economic growth (SDG 8·5), and universal health coverage (UHC; SDG 3·8).

But for all the positive movement in aligning national capacities with the SDGs, the report portrays the steep chasm between those who are secure and those who are not. By the most basic standards, only 45% of the world’s population are covered by at least one social benefit, leaving at least 4 billion people outside of the scope of protection, with Africa, Asia, and Arab States the farthest behind. Nearly 1·3 billion of those people are children. Notably, countries spend on average only 1·1% of GDP on social protection benefits for those younger than 14 years. This chronic underinvestment, left uncorrected, perpetuates staggering long-term inequities.

The report identifies UHC as a crucial piece of social protection, as the need for access to health care is independent of employment status and crosses the lifespan. It might be the most transformative of protections, but also the most fraught, from contracting programmes threatening health services in high-income countries to virtually non-existent long-term care access in low-income countries. Over half of the people in rural areas of the world lack any health coverage, compared with 22% of people in urban areas. Compounding rural–urban inequity is the shortage of health workers, estimated at 13·6 million. To improve access and to achieve UHC, an additional 10 million health workers will be needed. In meeting these care service needs, however, there is also great opportunity for job creation, reducing poverty, and improving conditions for health workers.

As countries navigate the challenging path to improving social protection and realising the SDGs, there is reason to return to the values that drive this work. Fittingly, International Human Solidarity Day is Dec 20, an observance that encourages governments to respect their commitments, promote poverty eradication, and celebrate unity in diversity. As there are many meanings for social security, there are many meanings for solidarity. It is not simply reciprocity or fostering prosocial interventions by government. It is cohesion. The sum will be greater than the parts. In creating a better world, sustainable development goals must also be solidarity development goals. Goals that can only be met by revisiting the fundamental values of promoting unity, harmony, and collective security—in solidarity.

Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: a multistage analysis

The Lancet
Dec 16, 2017 Volume 390 Number 10113 p2605-2738  e51-e59
http://www.thelancet.com/journals/lancet/issue/current

Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: a multistage analysis
David M Pigott, Aniruddha Deshpande, Ian Letourneau, Chloe Morozoff, Robert C Reiner Jr, Moritz U G Kraemer, Shannon E Brent, Isaac I Bogoch, Kamran Khan, Molly H Biehl, Roy Burstein, Lucas Earl, Nancy Fullman, Jane P Messina, Adrian Q N Mylne, Catherine L Moyes, Freya M Shearer, Samir Bhatt, Oliver J Brady, Peter W Gething, Daniel J Weiss, Andrew J Tatem, Luke Caley, Tom De Groeve, Luca Vernaccini, Nick Golding, Peter Horby, Jens H Kuhn, Sandra J Laney, Edmond Ng, Peter Piot, Osman Sankoh, Christopher J L Murray, Simon I Hay
2662
Open Access
Summary
Background
Predicting when and where pathogens will emerge is difficult, yet, as shown by the recent Ebola and Zika epidemics, effective and timely responses are key. It is therefore crucial to transition from reactive to proactive responses for these pathogens. To better identify priorities for outbreak mitigation and prevention, we developed a cohesive framework combining disparate methods and data sources, and assessed subnational pandemic potential for four viral haemorrhagic fevers in Africa, Crimean–Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus disease.
Methods
In this multistage analysis, we quantified three stages underlying the potential of widespread viral haemorrhagic fever epidemics. Environmental suitability maps were used to define stage 1, index-case potential, which assesses populations at risk of infection due to spillover from zoonotic hosts or vectors, identifying where index cases could present. Stage 2, outbreak potential, iterates upon an existing framework, the Index for Risk Management, to measure potential for secondary spread in people within specific communities. For stage 3, epidemic potential, we combined local and international scale connectivity assessments with stage 2 to evaluate possible spread of local outbreaks nationally, regionally, and internationally.
Findings
We found epidemic potential to vary within Africa, with regions where viral haemorrhagic fever outbreaks have previously occurred (eg, western Africa) and areas currently considered non-endemic (eg, Cameroon and Ethiopia) both ranking highly. Tracking transitions between stages showed how an index case can escalate into a widespread epidemic in the absence of intervention (eg, Nigeria and Guinea). Our analysis showed Chad, Somalia, and South Sudan to be highly susceptible to any outbreak at subnational levels.
Interpretation
Our analysis provides a unified assessment of potential epidemic trajectories, with the aim of allowing national and international agencies to pre-emptively evaluate needs and target resources. Within each country, our framework identifies at-risk subnational locations in which to improve surveillance, diagnostic capabilities, and health systems in parallel with the design of policies for optimal responses at each stage. In conjunction with pandemic preparedness activities, assessments such as ours can identify regions where needs and provisions do not align, and thus should be targeted for future strengthening and support.
Funding
Paul G Allen Family Foundation, Bill & Melinda Gates Foundation, Wellcome Trust, UK Department for International Development

Deploy vaccines to fight superbugs

Nature 
Volume 552 Number 7684 pp147-278  14 December 2017
http://www.nature.com/nature/current_issue.html

Comment
Deploy vaccines to fight superbugs
Immunizations combined with antibiotics could be our best shot at combating drug-resistant microbes, argue Rino Rappuoli, David E. Bloom and Steve Black.
[Initial text]
Bacteria, viruses, parasites and fungi that are resistant to drugs cause 700,000 deaths each year. By 2050, such ‘superbugs’, inured to treatments, could cause up to 10 million deaths annually and cost the global economy US$100 trillion12. If this happens, antimicrobial resistance (AMR) will be a bigger killer than cancer is now.
Antimicrobials alone won’t be able to mitigate the threat. The supply of naturally occurring antibiotics seems thin. And efforts to engineer new ones have floundered.
We think that vaccines could be a key way to stem the crisis. To launch a global strategic effort to prioritize their development, scientists, policymakers and key stakeholders need to see antibiotics and vaccines as complementary tools. Here we focus on antibiotic-resistant bacteria, for which the need for solutions is most urgent…

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

New England Journal of Medicine
December 14, 2017  Vol. 377 No. 24
http://www.nejm.org/toc/nejm/medical-journal

Original Article
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
Lars Ostergaard, M.D., Ph.D., Timo Vesikari, M.D., Ph.D., Judith Absalon, M.D., M.P.H., Johannes Beeslaar, M.D., Brian J. Ward, M.D., C.M., Shelly Senders, M.D., Joseph J. Eiden, M.D., Ph.D., Kathrin U. Jansen, Ph.D., Annaliesa S. Anderson, Ph.D., Laura J. York, Ph.D., Thomas R. Jones, Ph.D., Shannon L. Harris, Ph.D., Robert O’Neill, Ph.D., David Radley, M.S., Roger Maansson, M.S., Jean-Louis Prégaldien, M.S., John Ginis, B.S., Nina B. Staerke, M.D., and John L. Perez, M.D., for the B1971009 and B1971016 Trial Investigators*
N Engl J Med 2017; 377:2349-2362 December 14, 2017
DOI: 10.1056/NEJMoa1614474
Background
MenB-FHbp is a licensed meningococcal B vaccine targeting factor H–binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.

Critical dynamics in population vaccinating behavior

PNAS – Proceedings of the National Academy of Sciences of the United States
of America

http://www.pnas.org/content/early/
[Accessed 16 December 2017]

Biological Sciences – Ecology:
Critical dynamics in population vaccinating behavior
Demetri Pananos, Thomas M. Bury, Clara Wang, Justin Schonfeld, Sharada P. Mohanty, Brendan Nyhan, Marcel Salathé, and Chris T. Bauch
PNAS 2017 ; published ahead of print December 11, 2017, doi:10.1073/pnas.1704093114
Significance
Complex adaptive systems exhibit characteristic dynamics near tipping points such as critical slowing down (declining resilience to perturbations). We studied Twitter and Google search data about measles from California and the United States before and after the 2014–2015 Disneyland, California measles outbreak. We find critical slowing down starting a few years before the outbreak. However, population response to the outbreak causes resilience to increase afterward. A mathematical model of measles transmission and population vaccine sentiment predicts the same patterns. Crucially, critical slowing down begins long before a system actually reaches a tipping point. Thus, it may be possible to develop analytical tools to detect populations at heightened risk of a future episode of widespread vaccine refusal.
Abstract
Vaccine refusal can lead to renewed outbreaks of previously eliminated diseases and even delay global eradication. Vaccinating decisions exemplify a complex, coupled system where vaccinating behavior and disease dynamics influence one another. Such systems often exhibit critical phenomena—special dynamics close to a tipping point leading to a new dynamical regime. For instance, critical slowing down (declining rate of recovery from small perturbations) may emerge as a tipping point is approached. Here, we collected and geocoded tweets about measles–mumps–rubella vaccine and classified their sentiment using machine-learning algorithms. We also extracted data on measles-related Google searches. We find critical slowing down in the data at the level of California and the United States in the years before and after the 2014–2015 Disneyland, California measles outbreak. Critical slowing down starts growing appreciably several years before the Disneyland outbreak as vaccine uptake declines and the population approaches the tipping point. However, due to the adaptive nature of coupled behavior–disease systems, the population responds to the outbreak by moving away from the tipping point, causing “critical speeding up” whereby resilience to perturbations increases. A mathematical model of measles transmission and vaccine sentiment predicts the same qualitative patterns in the neighborhood of a tipping point to greatly reduced vaccine uptake and large epidemics. These results support the hypothesis that population vaccinating behavior near the disease elimination threshold is a critical phenomenon. Developing new analytical tools to detect these patterns in digital social data might help us identify populations at heightened risk of widespread vaccine refusal.

Ethical review and qualitative research competence: Guidance for reviewers and applicants

Research Ethics
Volume 13, Issue 3-4, July-October 2017
http://journals.sagepub.com/toc/reab/current

Articles
Ethical review and qualitative research competence: Guidance for reviewers and applicants
Julie Mooney-Somers, Anna Olsen
First Published November 30, 2016; pp. 128–138
Preview
It is difficult to consider, describe or address the ethical issues particular to qualitative research without experience and understanding of the technicalities of qualitative methodologies. The Australian National Statement on the Ethical Conduct of Research Involving Humans charges researchers with a responsibility to demonstrate that they have the appropriate experience, qualifications and competence for their proposed research. Ethical review committees have the responsibility to judge claimed research competence. This article provides practical guidance to researchers and review committees on using formal qualifications and training, explicit claims of competence, and markers of in/competence to assess qualitative research competence.

Research with pregnant women: a call to action

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research with pregnant women: a call to action
Despite a global need for the use of medication during pregnancy, the medical research community lacks robust evidence for safety and efficacy of treatments and preventives often taken by pregnant women.
Authors: Margaret Olivia Little and Marisha N. Wickremsinhe
Citation: Reproductive Health 2017 14(Suppl 3):156
Published on: 14 December 2017

Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research
Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials
Authors: Melba F. Gomes, Vânia de la Fuente-Núñez, Abha Saxena and Annette C. Kuesel
Citation: Reproductive Health 2017 14(Suppl 3):172
Published on: 14 December 2017
Abstract
Background
For 30 years, women have sought equal opportunity to be included in trials so that drugs are equitably studied in women as well as men; regulatory guidelines have changed accordingly. Pregnant women, however, continue to be excluded from trials for non-obstetric conditions, though they have been included for trials of life-threatening diseases because prospects for maternal survival outweighed potential fetal risks. Ebola virus disease is a life-threatening infection without approved treatments or vaccines. Previous Ebola virus (EBOV) outbreak data showed 89–93% maternal and 100% fetal/neonatal mortality. Early in the 2013–2016 EBOV epidemic, an expert panel pointed to these high mortality rates and the need to prioritize and preferentially allocate unregistered interventions in favor of pregnant women (and children). Despite these recommendations and multiple ethics committee requests for their inclusion on grounds of justice, equity, and medical need, pregnant women were excluded from all drug and vaccine trials in the affected countries, either without justification or on grounds of potential fetal harm. An opportunity to offer pregnant women the same access to potentially life-saving interventions as others, and to obtain data to inform their future use, was lost. Once again, pregnant women were denied autonomy and their right to decide.
Conclusion
We recommend that, without clear justification for exclusion, pregnant women are included in clinical trials for EBOV and other life-threatening conditions, with lay language on risks and benefits in information documents, so that pregnant women can make their own decision to participate. Their automatic exclusion from trials for other conditions should be questioned.

Nubia’s mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research
Nubia’s mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola
Authors: Séverine Caluwaerts
Citation: Reproductive Health 2017 14(Suppl 3):157
Published on: 14 December 2017
Abstract
During the 2014–2016 Ebola epidemic, Médecins Sans Frontières (MSF) treated Ebola-positive pregnant women in its Ebola Treatment Centers (ETCs). For pregnant women with confirmed Ebola virus disease, inclusion in clinical vaccine/drug/therapeutic trials was complicated. Despite their extremely high Ebola-related mortality in previous epidemics (89–93%) and a neonatal mortality of 100%, theoretical concerns about safety of vaccines and therapeutics in pregnancy were invoked, limiting pregnant women’s access to an experimental live attenuated vaccine and brincidofovir, an experimental antiviral. Favipiravir, another experimental antiviral, was made available to pregnant women only after extensive negotiations and under a ‘Monitored Emergency Use of Unregistered and Experimental Interventions’ (MEURI) protocol. This paper describes the case of a pregnant woman who presented to the ETCs near the end of the Ebola epidemic in Guinea. The pregnant patient was admitted with confirmed Ebola disease. She was previously denied access to potentially protective vaccination due to pregnancy, and access to experimental ZMapp was only possible through a randomized clinical trial (presenting a 50% chance of not receiving ZMapp). She received favipiravir, but died of Ebola-related complications. The infant, born in the ETC, tested positive for Ebola at birth. The infant received ZMapp (under MEURI access outside of the clinical trial), an experimental drug GS5734, and a buffy coat of an Ebola survivor, and survived. Though the infant did have access to experimental therapeutics within 24 h of birth, access to other experimental compounds for her mother was denied, raising serious ethical concerns.

Ethical considerations in developing an evidence base for pre-exposure prophylaxis in pregnant women

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research
Ethical considerations in developing an evidence base for pre-exposure prophylaxis in pregnant women
Though many women in need of access to HIV preventive regimes are pregnant, there is a dearth of data to guide these care decisions. While oral pre-exposure prophylaxis (PrEP) has been shown to prevent HIV inf…
Authors: Kristen A. Sullivan and Anne D. Lyerly
Citation: Reproductive Health 2017 14(Suppl 3):171
Published on: 14 December 2017

Ethical challenges posed by clinical trials in preterm labor: a case study

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research
Ethical challenges posed by clinical trials in preterm labor: a case study
This paper explores the ethical implications of a randomized double-blind clinical trial aimed to determine effectiveness and safety of an oxytocin receptor antagonist versus a betamimetic in the treatment of …
Authors: Sofía P. Salas
Citation: Reproductive Health 2017 14(Suppl 3):168
Published on: 14 December 2017

Enrolling pregnant women in research: ethical challenges encountered in Lao PDR (Laos)

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Research
Enrolling pregnant women in research: ethical challenges encountered in Lao PDR (Laos)
Laos has the highest maternal mortality ratio in mainland Southeast Asia but there has been little research conducted with pregnant women. We aim to discuss ethical challenges in enrolling pregnant women in re…
Authors: Vilada Chansamouth, Rose McGready, Danoy Chommanam, Soukanya Homsombath, Mayfong Mayxay and Paul N. Newton
Citation: Reproductive Health 2017 14(Suppl 3):167
Published on: 14 December 2017

The global forum on bioethics in research meeting, “ethics of research in pregnancy”: emerging consensus themes and outputs

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 December 2017]

Commentary
The global forum on bioethics in research meeting, “ethics of research in pregnancy”: emerging consensus themes and outputs
Research during pregnancy is affected by multiple ethical challenges which have not received sufficient international attention and consideration from the bioethics, clinical, and policymaking communities work…
Authors: Adrienne Hunt, Natalie Banner and Katherine Littler
Citation: Reproductive Health 2017 14(Suppl 3):158
Published on: 14 December 2017

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Science Translational Medicine
13 December 2017    Vol 9, Issue 420
http://stm.sciencemag.org/

Research Articles
Durability and correlates of vaccine protection against Zika virus in rhesus monkeys
By Peter Abbink, Rafael A. Larocca, Kittipos Visitsunthorn, Michael Boyd, Rafael A. De La Barrera, Gregory D. Gromowski, Marinela Kirilova, Rebecca Peterson, Zhenfeng Li, Ovini Nanayakkara, Ramya Nityanandam, Noe B. Mercado, Erica N. Borducchi, Abishek Chandrashekar, David Jetton, Shanell Mojta, Priya Gandhi, Jake LeSuer, Shreeya Khatiwada, Mark G. Lewis, Kayvon Modjarrad, Richard G. Jarman, Kenneth H. Eckels, Stephen J. Thomas, Nelson L. Michael, Dan H. Barouch
Science Translational Medicine13 Dec 2017 Full Access
Not all vaccines afford robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination
Patience pays off
As an individual may not encounter the pathogen for years after they have been vaccinated, efficacious vaccines typically require induction of long-lasting immunity. Abbink and colleagues vaccinated nonhuman primates with one of several candidate Zika virus vaccines and then waited an entire year before conducting a viral challenge. These vaccines had all shown promising results in previous experiments with a more immediate challenge, but here, one vaccine faltered, likely due to waning antibodies. The researchers performed more experiments to suggest that circulating antibodies are mediating protection for these vaccines. These results are useful for Zika virus vaccine development and instructive for vaccine development in general.
Abstract
An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector–based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.